Chrysalis BioTherapeutics Selected to Present at Respiratory Innovatio...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: May 19, 2024

Upneeq® Wins 2024 Shape Skin Award, “Best for Lift”, in the Professional Treatment Category • Dillard’s, Inc. Announces $0.25 Cash Dividend • The AZEK Company Receives NYSE Notice Regarding Filing of Form 10-Q for the Fiscal Quarter Ended March 31, 2024 • Avangrid to Be Acquired by Iberdrola • Statement by the Prime Minister on Tamil Genocide Remembrance Day • Aramco and Spiritus to Advance Direct Air Capture Technology, Investment by Aramco Ventures • WOMEN'S HEALTHCARE COMPANY WATKINS-CONTI RECEIVES FDA 510(K) CLEARANCE FOR NEW STRESS URINARY INCONTINENCE DEVICE YŌNI.FIT& • Energy Vault Holdings, Inc. Announces Inducement Grants Under NYSE Listing Rule 303A.08 • Sacred Heart Celebrates 125th Anniversary • Federal, provincial and territorial ministers gather to support culture and heritage at annual meeting • Xylem Inc. Declares Second Quarter Dividend of 36 Cents per Share • Rockwell Institute Celebrates Highest Real Estate Exam Pass Rates for First-Time Test Takers in the State of Washington • After Launching Massive Camp Giveaway for NYC Families Affected by "Summer Rising" Crisis, Brains & Motion Education (BAM!) • Angels Helpers NYC 2024 Charity Gala Raises Funds for Harlem School of the Arts, Highbridge Voices • Historic Inaugural Class Graduates from OSU College of Osteopathic Medicine at the Cherokee Nation • HERImpact: Entrepreneurship for Impact Program Kicks Off in Chicago, Empowering Women Entrepreneurs • Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer • L.A. Care and Blue Shield of California Promise Health Plans Unveil New, Vibrant Community Resource Center in Panorama City with • May and Stanley Smith Charitable Trust Partners with American Indian College Fund to Support Native Student Veterans • Historic Bellevue House reopens

Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit

GALVESTON, Texas , May 06 /Businesswire/ - Chrysalis BioTherapeutics today announced it was selected to participate in the 2024 Respiratory Innovation Summit (RIS) at the American Thoracic Society Meeting in San Diego.

The Respiratory Innovation Summit (RIS) has been established by the American Thoracic Society to unite innovators, investors, clinicians, and advocacy groups to help create powerful new treatments for deadly and crippling diseases of the lungs and airways. Each year, companies developing respiratory devices and therapeutics are invited to submit abstracts describing how their innovative therapies may change the treatment of lung disease.

This year, Chrysalis was selected as one of six “Critical Care Therapeutic Innovator” companies for oral presentation at the Summit.

“To be selected to present at the Respiratory Summit is a great honor for Chrysalis and confirms that experts in this field recognize the potential of TP508 (Chrysalin™) to prevent progression of acute lung injury,” said Dr. Darrell Carney, Chrysalis CEO.

Chrysalis is developing TP508, a natural thrombin-derived peptide, to treat Acute Respiratory Distress Syndrome (ARDS) which affects over a million people each year with up to 35 percent dying within weeks of diagnosis. Of those who survive, most experience decreased lung function or progressive fibrosis.

“Based on preclinical results with COVID and acute lung injury models, we expect TP508 to stop the progression of ARDS,” said Dr. Laurie Sower, Chrysalis EVP.

Chrysalis has received FDA IND approval to proceed into human clinical trials and has initiated a Phase 1 Safety/PK trial, with subsequent trials in ARDS patients to follow as the company receives funding for these trials.

Chrysalis BioTherapeutics, Inc. is a privately held Galveston, TX-based biopharmaceutical company with world-wide license to the TP508 technology from the University of Texas System and the University of Texas Medical Branch (UTMB). Chrysalis BioTherapeutics is currently seeking investors and pharma partners for pulmonary and other indications including TBI, radiation therapy and mitigation chronic pulmonary diseases. Chrysalin™ drug development programs have been funded by NIH and the Biomedical Advanced Research and Development Authority (BARDA) both part of the U.S. Department of Health and Human Services. For more information contact dcarney@chrysbio.com or visit www.chrysbio.com.